High-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage - Part I.

Completed

Phase N/A Results

Summary of Purpose

To test the hypothesis that higher doses of tirilazad mesylate are required to prevent vasospasm and improve outcome in women with subarachnoid hemorrhage (SAH).

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 13 August 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • Pharamacia-Upjohn, Inc., Kalamazoo, MI

Trial Design

Parallel, multi-center, randomized, stratified trial of 819 patients at 56 neurological centers in Europe, Australia, New Zealand and South Africa.

Contacts

Not available